Anzeige
Mehr »
Login
Samstag, 23.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
325 Leser
Artikel bewerten:
(2)

Auxilius Revenue Grows 800% in 2023, Raises $10M to Scale Clinical Trial Financial Management Platform

Finanznachrichten News

Rapid growth and strong partnerships with over 50 innovative biopharma companies power Auxilius's momentum ahead of its latest fundraise

NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Auxilius, the first Clinical Trial Financial Management (CTFM) software which enables life science finance, accounting, and clinical operations teams to automate accounting workflows and improve clinical R&D forecast accuracy, has raised $10M in additional financing, led by SignalFire. This fundraise came on the back of a 2023 that saw annual recurring revenue (ARR) grow 800% year-over-year, expanding partnerships with over 50 biopharma companies.

Adam Weisman & Erin Warner Guill

Adam Weisman & Erin Warner Guill

Particularly when the biopharma industry lacks access to capital, cost management is paramount. But the existing collection of clinical and ERP systems available leaves a massive gap when it comes to managing biopharma's largest cost: clinical trials. And with $250B spent on R&D every year, this gap is big. This leaves finance and accounting teams to manage clinical trial budgets on massive spreadsheets that are time-consuming to maintain, susceptible to crashing, and fail to provide insights to drive their business forward. Despite a 44% increase in R&D spend over the past decade, the rate of new drug approvals has remained flat - making R&D efficiency more important than ever (source).

By filling this critical gap and optimizing the management of biopharma's single largest, most variable cost, Auxilius empowers its customer to manage clinical spend with rigor, manage risk and runway, and improve team efficiency.

"In 2023, we established CTFM as a critical function in any biopharma company sponsoring clinical research. And while CTFM hasn't seen material innovation since the advent of the spreadsheet, efficient and effective financial decision-making has never been more important. Our rapid growth and adoption is a testament to our underlying value proposition and the establishment of Auxilius as an essential part of the biopharma toolstack. Looking forward, we will continue to invest in product innovation and scale our go-to-market capabilities to further build momentum in the category we're creating." - Adam Weisman, CEO and co-founder, Auxilius

"Auxilius marks a significant leap forward in addressing the complex financial management challenges inherent in clinical trial operations within biopharma. As we look ahead, the impact of Auxilius extends beyond mere efficiency gains; it holds the potential to revolutionize how clinical R&D expenses are managed, empowering biotech and pharma companies to allocate resources more effectively and accelerate the pace of innovation in medical breakthroughs." - Lisa Liu, Principal SignalFire

Auxilius clients see material improvements in their efficiency and effectiveness at managing clinical trial budgets:

  • 75% reduction in time spent on monthly accounting tasks, resulting in faster close
  • 40% improvement in study budget accuracy
  • 80% of customers identifying vendor billing mistakes within their first 60 days on the platform, often preventing overcharges of more than $1M

The over 50 customers reflect a broad range of the life science industry, in terms of diversity in therapeutic focus, filing status, portfolio scope, geographic footprint, external vendors and auditors. New customers who came on board in 2023 include Trevi Therapeutics, TG Therapeutics, Invivyd and Repare.

In addition to ongoing innovation and customer growth, Auxilius has also strengthened its relationships with Big 4 accounting firms and other organizations to help biopharma companies in their digitization journey.

About Auxilius

Auxilius is a software company designed to help biopharma companies tackle the unique operational, financial, and accounting needs of clinical trials. The company has built FP&A and Accounting software that replaces manual processes and allows sponsors to take control over trial costs and clinical vendors through study-level budgeting, planning and financial close. Currently, the company works with over 50 sponsors including emerging Biotech and mature, public Pharma. For more information, visit?www.auxili.us, or follow on LinkedIn at https://www.linkedin.com/company/auxilius/?

Contact Information

Peter Kinchley
Head of Marketing
pkinchley@auxili.us
617-548-2295

SOURCE: Auxilius

.

View the original press release on newswire.com.

© 2024 ACCESSWIRE
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.